Special Issue "Radiotherapy for Genitourinary Cancer"
Deadline for manuscript submissions: 31 December 2023 | Viewed by 11827
Interests: radiation oncology; intensity-modulated radiation therapy; prostate cancer; head and neck cancer; cervical cancer; outcomes research
Interests: muscle-invasive bladder cancer; prostate cancer; oligometastasis; robot-assisted surgery; intracorporeal urinary diversion; ileal neobladder; ileal conduit
Special Issues, Collections and Topics in MDPI journals
Radiation therapy is one of the most important treatment modalities for genitourinary cancer. In addition to definitive radiation therapy for primary lesions, palliative radiation therapy of metastatic lesions for pain relief is also performed, especially for prostate cancer. In recent years, attempts have been made to improve the prognosis of patients with metastatic cancer by using radiation therapy to target the primary tumor.
Recently, various radiation therapy methods have also been developed and favorable outcomes have been reported. At present, however, it is not clear which treatment method should be selected for which type of cancer and what dosage should be used. On the other hand, there have been attempts to improve patients’ prognosis by combining radiotherapy with systemic treatment.
Radiation therapy is certainly an effective treatment for genitourinary cancer. However, it is also true that there are many aspects that are yet to be elucidated. In addition, biomarkers used for predicting treatment efficacy are currently being extensively studied. Conversely, the definition of recurrence when using tumor markers differs between surgical therapy and radiation therapy, which causes significant issues.
In this Special Issue, we invite you to discuss various topics related to radiotherapy, such as treatment outcomes, biomarkers used to predict diagnosis and treatment efficacy, and issues related to the definition of recurrence.
Dr. Natsuo Tomita
Prof. Dr. Takuya Koie
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- radiation therapy
- genitourinary cancer
- definitive therapy
- palliative therapy
- radiation and systemic therapy